How to Choose Between GH Secretagogues — Ipamorelin vs CJC-1295 vs GHRP-2 vs Sermorelin

Growth hormone secretagogues (GHS) are the most popular class of research peptides. They all share one endpoint — increasing growth hormone release — but they achieve it through different receptors, produce different GH pulse patterns, and come with distinct side-effect profiles. Choosing the right one depends on your goals, tolerance for side effects, and whether you prefer simplicity or optimization.

The two receptor systems

Understanding GHS selection starts with two receptor types:

GHRH receptor (Growth Hormone Releasing Hormone receptor)

Natural ligand: GHRH (produced by the hypothalamus)

Mechanism: Directly stimulates somatotrophs in the anterior pituitary to synthesize and release GH

Peptides acting here: Sermorelin, CJC-1295, Tesamorelin, Modified GRF (1-29)

Key characteristic: GHRH-receptor peptides amplify the natural GH pulse. They work best when the pituitary is already primed for release (during natural GH pulse windows). They have minimal effect when somatostatin tone is high (i.e., between pulses).

Ghrelin receptor (GHS-R1a / Growth Hormone Secretagogue Receptor)

Natural ligand: Ghrelin (produced primarily by the stomach)

Mechanism: Stimulates GH release via a pathway distinct from GHRH, and partially suppresses somatostatin

Peptides acting here: Ipamorelin, GHRP-2, GHRP-6, Hexarelin, MK-677 (oral non-peptide)

Key characteristic: Ghrelin-receptor peptides can initiate GH release even during inter-pulse periods because they partially suppress somatostatin. They work somewhat independently of the body's natural timing.

Why combining both works

The combination of a GHRH analog + ghrelin mimetic (e.g., CJC-1295 + Ipamorelin) produces synergistic GH release — greater than either alone. The ghrelin mimetic suppresses somatostatin and primes the pituitary, while the GHRH analog provides the direct stimulatory signal. This mimics the natural dual-signal system more closely.

Head-to-head comparison

Ipamorelin

Receptor: Ghrelin receptor (GHS-R1a)

GH release magnitude: Moderate (3–6× baseline)

Selectivity: Highly selective for GH — minimal cortisol, prolactin, or ACTH elevation

Pros:

• Cleanest side-effect profile of any GHS
• No significant hunger increase (unlike GHRP-6)
• No cortisol elevation
• Predictable, consistent GH pulses
• Excellent for long-term use

Cons:

• Lower GH release magnitude than GHRP-2 or Hexarelin
• Less effective as a standalone without GHRH analog pairing

Best for: Users who want clean GH elevation without side effects. The default choice for most protocols. Ideal for anti-aging, sleep improvement, and body composition goals where aggressive GH elevation isn't needed.

CJC-1295 (with DAC)

Receptor: GHRH receptor

GH release pattern: Sustained elevation (days) rather than acute pulses

Half-life: 6–8 days (due to Drug Affinity Complex binding to albumin)

Pros:

• Once or twice weekly dosing (convenience)
• Sustained IGF-1 elevation
• No injection timing requirements relative to meals

Cons:

• Eliminates natural GH pulsatility (continuous elevation instead of pulses)
• Cannot be "turned off" — if side effects occur, they persist for days
• Some evidence that pulsatile GH is physiologically superior to continuous GH
• GH bleed (constant low-level elevation) rather than natural spike pattern

Best for: Users prioritizing convenience over physiological precision. Those who want steady-state IGF-1 elevation for recovery and body composition. Not ideal for those who want to preserve natural GH pulsatility.

Modified GRF (1-29) / CJC-1295 without DAC

Receptor: GHRH receptor

GH release pattern: Acute pulse (similar to natural GHRH pulse)

Half-life: ~30 minutes

Pros:

• Produces physiological-style GH pulses (preserves pulsatility)
• Excellent synergy when combined with ghrelin mimetics
• Short half-life means rapid clearance if side effects occur
• Better replicates natural GH physiology

Cons:

• Requires 2–3× daily injection (inconvenient)
• Must be timed with natural GH pulse windows for maximum effect
• Less effective as a standalone (needs ghrelin mimetic pairing)

Best for: Users who want the most physiological GH pattern and are willing to inject multiple times daily. The standard GHRH component in the popular "CJC-1295/Ipamorelin" combination.

GHRP-2

Receptor: Ghrelin receptor (GHS-R1a)

GH release magnitude: High (5–10× baseline — strongest of the GHRPs)

Selectivity: Less selective than ipamorelin — elevates cortisol and prolactin at higher doses

Pros:

• Strongest GH release of any ghrelin-receptor peptide
• Effective at lower doses than GHRP-6
• Moderate hunger increase (less than GHRP-6)
• Good for those needing aggressive GH elevation

Cons:

• Dose-dependent cortisol elevation (at >200 mcg)
• Prolactin elevation possible (typically mild)
• More side effects than ipamorelin
• Hunger increase (moderate but consistent)

Best for: Users who need maximal GH output and are willing to accept more side effects. Bodybuilders, those recovering from significant injury, or cases where ipamorelin alone doesn't produce sufficient response.

GHRP-6

Receptor: Ghrelin receptor (GHS-R1a)

GH release magnitude: Moderate-high (4–8× baseline)

Selectivity: Poor — significant cortisol, prolactin, and intense hunger stimulation

Pros:

• Strong GH release
• Pronounced appetite stimulation (beneficial for underweight individuals or "hardgainers")
• Well-studied pharmacology

Cons:

• Intense hunger (often unmanageable for those trying to lose fat)
• Cortisol and prolactin elevation
• Water retention
• Worse side-effect profile than ipamorelin or GHRP-2

Best for: Individuals who struggle to eat enough (cancer cachexia, recovery from illness, extreme ectomorphs). The hunger effect is a feature, not a bug, for this population. Poor choice for anyone concerned about body fat.

Hexarelin

Receptor: Ghrelin receptor (strongest affinity)

GH release magnitude: Highest initial response of any GHS

Half-life: Similar to other GHRPs

Pros:

• Most powerful acute GH release
• Cardioprotective effects (independent of GH, via cardiac GHS receptors)
• Interesting for cardiac research applications

Cons:

• Rapid desensitization (loses effectiveness within 2–4 weeks of continuous use)
• Significant cortisol and prolactin elevation
• Not suitable for long-term protocols without breaks
• Strongest tachyphylaxis of any GHS

Best for: Short-course use when maximum GH output is needed temporarily. The desensitization problem makes it impractical for ongoing protocols. Sometimes used in 2-week bursts with extended off-periods.

Sermorelin

Receptor: GHRH receptor

GH release pattern: Natural-style pulse

Half-life: ~10–20 minutes (very short)

Pros:

• FDA-approved history (for pediatric GH deficiency — now discontinued)
• Produces physiological GH pulses
• Well-characterized safety profile
• Good pituitary diagnostic tool

Cons:

• Very short half-life requires precise timing
• Lower potency than Modified GRF (1-29)
• Less stable in solution
• Largely superseded by CJC-1295 (no DAC) in practice

Best for: Those who want the safest, most established GHRH analog with the most clinical history. Prescribed by anti-aging clinics as a conservative first-line GHS.

Tesamorelin

Receptor: GHRH receptor

GH release pattern: Strong GHRH-style pulse

Half-life: ~30 minutes

FDA-approved: Yes (for HIV lipodystrophy)

Pros:

• FDA-approved with Phase III data
• Specifically demonstrated visceral fat reduction (~15% VAT decrease)
• Well-characterized safety in large trials
• Selective for visceral fat reduction over subcutaneous

Cons:

• Expensive (branded Egrifta)
• Approved only for HIV lipodystrophy (off-label for others)
• Requires daily injection

Best for: Those with elevated visceral adiposity who want the best-evidenced GHS for targeted visceral fat reduction. The only GHS with FDA approval and Phase III efficacy data for a body composition endpoint.

Decision framework

By primary goal

Goal	First Choice	Alternative
General anti-aging / wellness	Ipamorelin + Mod GRF	Sermorelin
Maximum GH output	GHRP-2 + Mod GRF	Hexarelin (short-term)
Fat loss (visceral)	Tesamorelin	CJC-1295 + Ipamorelin
Sleep improvement	Ipamorelin (pre-bed)	GHRP-2 (lower dose)
Injury recovery	GHRP-2 + Mod GRF	CJC-1295 (DAC) + Ipamorelin
Appetite stimulation	GHRP-6	GHRP-2
Convenience (less injections)	CJC-1295 (with DAC)	MK-677 (oral, non-peptide)

By side-effect tolerance

• Low tolerance: Ipamorelin (cleanest profile)
• Moderate tolerance: GHRP-2 + Mod GRF (strongest with manageable sides)
• High tolerance / short-term: Hexarelin (most powerful, rapid desensitization)

By experience level

• Beginner: Start with Ipamorelin alone → add Mod GRF if response is insufficient
• Intermediate: CJC-1295 (no DAC) + Ipamorelin combination
• Advanced: Rotate between GHRP-2 and Ipamorelin, paired with Mod GRF, with periodic breaks

Universal principles for all GHS

1. Dose on empty stomach: Insulin blunts GH release. Fast 2+ hours before injection.
2. Evening dosing preferred: Amplifies natural nocturnal GH pulse.
3. Don't exceed saturation dose: More peptide beyond the ceiling doesn't produce more GH.
4. Cycling preserves sensitivity: 5 days on / 2 off, or 4 weeks on / 2 weeks off.
5. Monitor IGF-1: Objective measure of whether your protocol is producing sustained GH elevation.
6. Blood glucose monitoring: Chronic GH elevation impairs insulin sensitivity. Track fasting glucose.